An Interactive Review on the Role of Tocotrienols in the Neurodegenerative Disorders

Ruth Naomi1, Nurul Husna Shafie2,3, Priyatharisni Kaniappan4

  • 1Department of Human Anatomy, Universiti Putra Malaysia, Serdang, Malaysia.

Frontiers in Nutrition
|November 12, 2021
PubMed

Insights

Tocotrienols (T3s), potent antioxidants, show promise in combating neurodegenerative diseases like Alzheimer's and Parkinson's by protecting neurons from oxidative stress and mitochondrial damage. Further clinical trials are needed to confirm their therapeutic efficacy.

Area of Science:

  • Neuroscience
  • Biochemistry
  • Pharmacology

Background:

  • Neurodegenerative disorders, including Alzheimer's and Parkinson's disease, represent a significant global health burden.
  • Oxidative stress, mitochondrial dysfunction, and nerve damage are key pathological mechanisms.
  • Reactive oxygen species (ROS) are implicated as a common damaging agent in neuronal cells.

Purpose of the Study:

  • To review and discuss the therapeutic potential of tocotrienols (T3s) for Alzheimer's and Parkinson's diseases.
  • To summarize the protective mechanisms of T3s against neurodegeneration based on in vitro and in vivo studies.

Main Methods:

  • Literature review of in vitro and in vivo studies investigating tocotrienols (T3s).
  • Analysis of the antioxidant and neuroprotective properties of T3s.

Main Results:

  • Tocotrienols (T3s) exhibit potent antioxidant properties.
  • T3s demonstrate potential in reversing neuronal damage and mitigating mitochondrial dysfunction.
  • Evidence from in vitro and in vivo studies supports the neuroprotective role of T3s.

Conclusions:

  • Tocotrienols (T3s) show promise as a therapeutic agent for neurodegenerative diseases due to their multifaceted protective mechanisms.
  • The clinical efficacy of T3s for Alzheimer's and Parkinson's disease remains under investigation due to a lack of clinical trials.

Related Concept Videos

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
740
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
293
Role of Neurotransmitters in Memory01:23

Role of Neurotransmitters in Memory

Neurotransmitters are integral to the brain's communication system, enabling neurons to transmit signals across synapses. This chemical exchange underpins various cognitive functions, including memory processes. The role of neurotransmitters in memory is multifaceted, influencing the encoding, consolidation, and retrieval of memories through their action on different neural circuits.
 Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is...
1.4K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
63
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
824
Neurogenesis and Regeneration of Nervous Tissue01:15

Neurogenesis and Regeneration of Nervous Tissue

In the CNS, neurogenesis, the birth of new neurons from stem cells, is limited to the hippocampus in adults. In other regions of the brain and spinal cord, neurogenesis is almost non-existent due to inhibitory influences from neuroglia, especially oligodendrocytes, and the absence of growth-stimulating cues. The myelin produced by oligodendrocytes in the CNS inhibits neuronal regeneration. Furthermore, astrocytes proliferate rapidly after neuronal damage, forming scar tissue that physically...
1.2K